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Synthesis of triazole-linked morpholino
oligonucleotides via CuI catalysed cycloaddition†
Matthew J. Palframan,‡ Rima D. Alharthy,§‡ Paulina K. Powalowska and
Christopher J. Hayes*
Triazole-linked morpholino (TLMO) oligonucleic acids were synthesised using the CuI catalysed (3 + 2)
azide–alkyne cycloaddition (CuAAC) reaction. The modiﬁed DNA analogues were incorporated into
13-mer sequences via solid phase synthesis. UV melting experiments showed that the TLMO modiﬁcation
gives higher Tm values than the corresponding
TLDNA modiﬁcation.
Introduction
Click chemistry has recently emerged as a powerful tool in the
field of nucleic acid research.1 In particular, the CuI catalysed
(3 + 2) azide–alkyne cycloaddition (CuAAC)2 has been used to
construct modified internucleotide linkages,3 to prepare
nucleic acid conjugates,4 and as a strand ligation tool.5 Zer-
rouki et al., designed a novel triazole-linked DNA analogue
(TLDNA) 1 using the CuAAC for oligomer elongation,6 and this
preliminary work has been significantly extended by Brown
et al. The artificial TLDNA retains good aqueous solubility, is
stable towards enzymatic degradation,3a and can be read by
polymerases,7 thus making it capable of in vitro transcription8
and rolling circle amplification.7 Furthermore, and perhaps
most impressively, Brown has demonstrated that genes con-
taining TLDNA 1 are functional in vivo in Escherichia coli and in
human cells.9 Given the biocompatibility of the TLDNA 1 with
DNA processing enzymes, it is curious that the thermal stabi-
lity of complementary duplexes is reduced. A recent study on
the structural basis of this phenomenon reported that the
TLDNA modification leads to less optimal stacking interactions
and distortion in the backbone at, and adjacent to, the site of
the triazole.10 Whilst high melting temperatures are not
required for all uses of modified nucleic acids, the formation
of stable duplexes is a requirement for therapeutic appli-
cations of oligonucleotides, and as such TLDNAs 1 do not rep-
resent good drug candidates.
As part of our own research aimed at developing thera-
peutic nucleic acids, we wondered if the thermal stability of tri-
azole-containing duplexes could be improved by the addition
of further modifications to the backbone. Thus we decided to
examine triazole-linked morpholino (TLMO) hybrid structures
2 (Fig. 1) as they could combine the ease of synthesis of the
TLDNAs 1 with the increased melting temperatures associated
with morpholino drug candidates.11,12 The TLMO hybrid 2 can
be disconnected to reveal the azide 4 and the alkyne-substi-
tuted morpholine 3 as potential precursors for the proposed
CuAAC reaction (Fig. 1).
Our initial route to 3 proceeded via the morpholine 6,
which was readily prepared from 5-methyl uridine 5 in good
yield by oxidative cleavage and subsequent reductive amin-
ation13 (Scheme 1). Although the N-alkylation of 6 did produce
Fig. 1 Approach to triazole-linked morpholino (TLMO) hybrid structures 2.
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the desired N-propargyl morpholine 3, only a low yield (36%)
of the desired alkyne was obtained. The main side reaction
was over alkylation of the thymine base in addition to N-alkyl-
ation of the morpholine, and an alternative route was explored.
Thus, oxidative cleavage of 5 in the presence of propargyl-
amine first gave 7, which upon treatment with sodium cyano-
borohydride/AcOH gave the desired product 3 in good overall
yield (71%) (Scheme 1).
Following formation of the alkyne-containing morpholine
nucleoside 3, our attention then turned to the synthesis of the
azide cycloaddition partner. Pleasingly, the 3′-TBSO-protected-
5′-deoxy-5′-azido thymidine 10 was readily prepared from the
alcohol 8 via a two-step sequence involving mesylate formation
and displacement with sodium azide. The 3′-OH-5′-deoxy-5′-
azido thymidine 4 was then synthesised from 10 via TBAF de-
protection (Scheme 2). Alternatively, 4 could be accessed directly
from thymidine via selective 5′-tosylation and subsequent azide
displacement using the known procedure (38%, 2 steps).14
With the required coupling partners in hand, we next exam-
ined the key Cu-catalysed cycloaddition step. As we needed
access the 3′-alcohol 12 to prepare phosphoramidite 13, we
explored two routes for its synthesis. The first was cyclo-
addition of 3 and the protected azide 10 (i.e. 3 + 10 → 11), fol-
lowed by TBS deprotection (11 → 12), and the second was
initial deprotection (10 → 4, Scheme 2) followed by cyclo-
addition with 3. A range of catalysts and solvents were initially
screened, and it was quickly found that the use of copper(I)
iodide in THF : tBuOH : H2O (3 : 2 : 1) with microwave heating
(80 °C) was optimal (Scheme 3).3a Under these conditions,
cycloaddition of the acetylene 3 with the TBS-protected azide
10 gave the triazole-linked morpholino (TLMO) dimer 11 in
good yield, and TBAF deprotection of 11 gave the desired
alcohol 12 in good yield (Scheme 3). We were pleased to find
that the alternative cycloaddition of 4 with 3 also proceeded in
good yield to give the alcohol 12 directly, and this was adopted
as our favoured route due to an improved overall yield and
easier of purification of 12 by column chromatography.
Finally, the TLMO 12 was converted to the 3′-cyanoethyl phos-
phoramidite 13 (74%) under standard conditions (Scheme 3).
To provide a direct comparison of the new TLMO hybrid 2
to the triazole-linked DNA analogue (TLDNA) 1, we next pre-
pared the phosphoramidite 17. This reagent facilitates in-
corporation of the triazole modification 1 into oligonucleotide
sequences via solid-phase synthesis as opposed to the frag-
ment ligation method used previously by Brown et al.10 The
phosphoramidite 17 was readily prepared from 14 via 3′-O-
alkylation to give the alkyne 15, Cu-catalysed cycloaddition
with 4 to provide the triazole-containing dimer 16 and then
conversion to 17 in the usual manner (Scheme 4).
Pleasingly, the modified phosphoramidites 13 and 17 were
fully compatible with solid-phase oligonucleotide synthesis
and we prepared the TLMO-containing oligomer 21 and the
known TLDNA oligomer 2210 in good yield (Table 1). Stock
aqueous solutions (pH 7) of the oligomers 21 and 22 were
readily prepared, and no adverse solubility issues were
observed. As Brown et al. have already reported UV-melting
data of 22 duplexed with its complimentary DNA strand 18,10
we also prepared 18 so that we could directly compare the Tm
values of 18 + 21, 18 + 22 and the unmodified duplex (18 + 20)
under the same conditions. In order to assess the potential
Scheme 1 Synthesis of the alkyne morpholine nucleoside 3.
Scheme 2 Synthesis of 5’-deoxy-5’-azido thymidine 4.
Scheme 3 Synthesis of 3’-cyanoethyl phosphoramidite 13.
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use of the TLMO-modification in therapeutically useful oligo-
mers, we also synthesised the complimentary RNA oligo-
nucleotide 19, as this simulates an intracellular mRNA target.
The integrity of the oligomers 18–22 was confirmed by ESI
mass spectrometry (Table 1) and HPLC (see ESI†).
Thermal stabilities of the TLMO 21, TLDNA 22, and unmodi-
fied DNA 20 duplexed with complimentary DNA 18 (Fig. 2) and
RNA 19 (Fig. 3) were then determined by UV melting experi-
ments15 (Table 2). Pleasingly, the Tm values of the control DNA
18 : DNA 20 (62.4 °C) (entry 1, Table 2), and the DNA
18 : TLDNA 22 (55.1 °C) (entry 3, Table 2) duplexes were in close
agreement with those reported previously by Brown (62.89 °C
and 55.30 °C respectively).10 The TLMO-containing oligomer 21
duplexed to DNA 18 gave a Tm value of 56.1 °C (entry 2,
Table 2), which represents a small increase (ΔTm 1.0 °C) over
that determined for 22, but still represents a significant
decrease from the unmodified DNA (ΔTm −6.3 °C). As men-
tioned above, duplexes with RNA provide a more meaningful
comparison for future therapeutic applications and the Tm
value of RNA 19 duplexed with unmodified DNA 20 was deter-
mined (58.5 °C) as a control (entry 4, Table 2). In contrast to
the duplexes with DNA, the Tm of
TLMO 21 (56.6 °C) was much
closer to that of the unmodified DNA : RNA than was TLDNA 22
(54.1 °C) with RNA 19 (ΔTm −1.9 °C for 21 vs. −4.4 °C for 22)
(entries 5 and 6, Table 2), thus demonstrating that the
addition of the morpholine modification can regain half of the
Tm lost by incorporating the triazole internucleotide linkage.
Further structural studies are underway in order to fully
assess the duplexes formed by TLMO-modified oligomers,
before selecting the best candidates for biological evaluation.
Scheme 4 Synthesis of 3’-cyanoethyl phosphoramidite 17.
Table 1 Sequences of oligonucleotides synthesised
Identifier Sequence 5′→ 3′
m/z
Calculated Found
18 (DNA) d(GCTGCAAACGTCG) 3953.55 3953.73
19 (RNA) GCUGCAAACGUCG 4133.49 4133.63
20 d(CGACGTTTGCAGC) 3944.53 3944.72
21a d(CGACG TGCAGC) 3944.64 3944.80
22b d(CGACG TGCAGC) 3945.63 3945.78
a indicates the position of the morpholine-triazole modification
13. b indicates the position of the triazole modification 17.
Fig. 3 UV-melting curves for oligomers (3 μM) 20, 21 and 22 duplexed
with RNA 19. Dotted lines represent cooling curves.




1 18 + 20 62.4 (61.9) N/A
2 18 + 21 56.1 (54.7) −6.3 (−7.2)
3 18 + 22 55.1 (54.1) −7.3 (−7.8)
4 19 + 20 58.5 (58.2) N/A
5 19 + 21 56.6 (55.3) −1.9 (−2.9)
6 19 + 22 54.1 (52.8) −4.4 (−5.4)
a Tm values for 3 µM oligo samples. Values in parentheses refer to
cooling curves. bΔTm per modification relative to the control DNA 20.
Fig. 2 UV-melting curves for oligomers (3 μM) 20, 21 and 22 duplexed
with DNA 18. Dotted lines represent cooling curves.
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5′-O-DMTr-5-methyluridine 5 (700 mg, 1.25 mmol) was dis-
solved in dry MeOH (10 mL) under an argon atmosphere.
Ammonium biborate (328 mg, 2.50 mmol), sodium periodate
(535 mg, 2.50 mmol) were added to the reaction mixture. After
stirring for 3 h at room temperature, the mixture was filtered
and sodium cyanoborohydride (155 mg, 2.50 mmol) was
added to the filtrate in one portion with stirring. Stirring con-
tinued for 6 h followed by evaporation to aﬀord a residue,
which was dissolved in EtOAc (10 mL), washed with brine (3 ×
10 mL). The organic phase was dried over MgSO4, filtered and
evaporated and purified by column chromatography eluting
with (CHCl3 : MeOH, 25 : 1) to aﬀord 6 as a colourless foam
(460 mg, 68% over three steps); Rf 0.28 (CHCl3 : MeOH, 25 : 1);
[α]25D +47 (c 0.61, CHCl3); νmax/cm
−1 (CHCl3) 3389, 2933, 2838,
2103, 1684, 1609, 1487 and 1455; 1H NMR (400 MHz, CDCl3)
7.47–7.42 (2H, m, Ar), 7.36–7.27 (6H, m, Ar), 7.32 (1H, s, C6H),
7.24–7.19 (1H, m, Ar), 6.84 (4H, d, J 8.9, Ar), 5.77 (1H, dd,
J 10.0, 2.7, C1′H), 4.01(1H, dtd, J 10.7, 4.9, 2.2, C4′H), 3.79 (6H,
s, OCH3), 3.27 (1H, dd, J 9.7, 5.1, C5′HH), 3.15 (1H, dd, J, 12.5,
2.7, C2′HH), 3.11–3.02 (2H, m, C5′HH and C3′HH), 2.68–2.58
(2H, m, C3′HH, C2′HH), 1.95 (3H, s, CH3);
13C NMR (100 MHz,
CDCl3) 164.1 (C), 158.5 (C), 150.4 (C), 144.8 (C), 135.9 (C),
135.8 (C), 135.4 (CH), 130.1 (CH), 130.0 (CH), 128.1 (CH), 127.8
(CH), 126.9 (CH), 113.1 (CH), 110.9 (C), 86.1 (C), 80.5 (CH),
78.0 (CH), 64.5 (CH2), 55.2 (CH3), 49.0 (CH2), 46.9 (CH2), 12.9
(CH3); HRMS m/z (ES+) Found 566.2245 (M + Na,
C31H33N3NaO6 requires 566.2245).
N′-propargyl-5′-O-DMTr-morpholino thymidine (3)
To a stirred solution of 5′-O-DMTr 5-methyluridine (5)
(725 mg, 1.29 mmol) in MeOH (12 mL) under an argon atmos-
phere, was added a solution of sodium periodate (304 mg,
1.42 mmol) in water (2 mL) dropwise over 5 min, followed by
propargyl amine (103 μL, 1.62 mmol) in one portion. The
resulting solution was stirred at room temperature for 3 hours,
during which time a white precipitate formed, the mixture was
filtered. To the stirred solution of the filtrate was added
sodium cyanoborohydride (162 mg, 2.58 mmol) followed by
the dropwise addition of acetic acid (110 μL, 1.93 mmol). The
reaction was stirred for 12 h at room temperature. The volatile
organic were removed by evaporation. The residue was parti-
tioned between sat. NaHCO3 (50 mL) and EtOAc (50 mL), the
aqueous layer was extracted with EtOAc (50 mL). The com-
bined organic layers were washed with brine (3 × 50 mL), dried
over MgSO4, and evaporated. The residue was purified by silica
gel chromatography, eluting with DCM :MeOH (40 : 1) to
aﬀord the title compound (529 mg, 71%) as a colourless foam;
Rf 0.17 (DCM :MeOH 25 : 1); [α]
25
D +30 (c 0.93, CHCl3); νmax/
cm−1 (CHCl3) 3390, 3196, 2955, 1933, 1838, 1694, 1633, 1609,
1583, 1491, 1456; 1H NMR (400 MHz, chloroform-d) δ 9.95
(1H, br s, NH), 7.48–7.44 (2H, m, Ar), 7.37–7.27 (6H, m, Ar),
7.32 (1H, s, C6H), 7.24–7.20 (1H, m, Ar), 6.84 (4H, d, J 8.9, Ar),
5.93 (1H, dd, J 9.8, 2.7, C1′H), 4.12 (1H, m, C4′H), 3.79 (6H, s,
OCH3), 3.45–3.44 (2H, m, NCH2CuCH), 3.34 (1H, dd, J 9.6,
5.3, C5′HH), 3.11 (1H, dd, J 9.6, 5.4, C5′HH), 2.97 (1H, br d,
J 10.5, C3′HAHB), 2.84 (1H, br d, J 11.4, C2′HH), 2.32 (1H, t,
J 2.3, CuCH), 2.34–2.23 (2H, m, C3′HH, C2′HH), 1.96 (3H, s,
CH3);
13C NMR (101 MHz, chloroform-d) 164.1 (C), 158.6 (C),
150.3 (C), 144.8 (C), 136.0 (C), 135.8 (C), 135.6 (CH), 130.13
(CH), 130.09 (CH), 128.2 (CH), 127.9 (CH), 126.9 (CH), 113.2
(CH), 110.9 (C), 86.2 (C), 79.6 (CH), 77.4 (C), 75.6 (CH), 74.5
(CH), 64.6 (CH2), 55.3 (CH3), 54.6 (CH2), 52.8 (CH2), 46.4
(CH2), 12.7 (CH3);
1H NMR (400 MHz, Benzene-d6) δ 9.88 (1H,
s, NH), 7.68 − 7.59 (2H, m, Ph), 7.52–7.40 (4H, m, Ar),
7.23–7.15 (2H, m, Ph), 7.11 − 7.01 (1H, m, Ph), 6.94 (1H, q,
J 1.2, C6H), 6.81–6.71 (4H, m, Ar), 5.95 (1H, dd, J 9.7, 2.7, C1′
H), 3.96–3.90 (1H, m, C4′H), 3.38 (1H, dd, J 9.6, 5.4, C5′HH),
3.30 (3H, s, OCH3), 3.29 (3H, s, OCH3) 3.17 (1H, dd, J 9.6, 5.1,
C5′HH), 3.01 (1H, dd, J 17.5, 2.4, NCHHCuCH), 2.92 (1H, dd,
J 17.5, 2.4, NCHHCuCH), 2.63 (1H, d, J 10.4, C2′HH), 2.47
(1H, d, J 10.9, C3′HH), 2.16 (1H, t, J 11.0, C3′HH), 2.16 (1H, t,
J 10.4, C3′HH), 1.90 (1H, t, J 2.4, CuCH), 1.66 (3H, d, J 1.2,
CH3);
13C NMR (101 MHz, Benzene-d6) δ 163. 9 (C4), 159.3 (2 ×
ArC), 150.3 (C2), 145.7 (PhC), 136.4 (ArC), 136.3 (ArC), 135.1
(C6H), 130.6 (4 × ArCH), 128.7 (2 × PhCH), 127.9 (2 × PhCH),
127.2 (PhCH), 113.6 (4 × ArCH), 110.8 (C5H), 86.7 (Ar3CO), 80.2
(C1′H), 78.0 (C), 75.9 (C4′H), 74.3 (CH), 65.1 (C5′H2), 54.8 (2 ×
OCH3 and C2′H2), 52.6 (C3′H2), 46.3 (NCH2C), 12.6 (CH3).
HRMS (ESI) C34H36N3O6 (M + H
+) requires 582.2599, found
582.2569.
5′-O-Mesyl-3′-O-tert-butyldimethylsilyl deoxythymidine (9)
To a stirred solution of 5′-OH-3′-O-tert-butyldimethylsilyl deoxy-
thymidine (1.06 g, 3.0 mmol) in dichloromethane (15 mL) at
0 °C was added triethylamine (0.84 mL, 6.0 mmol) followed by
the dropwise addition of mesyl chloride (277 μL, 3.6 mmol).
The resulting solution was stirred at 0 °C for 1 h, then warmed
to room temperature, and stirred for a further 3 hours. The
reaction was quenched by the addition of water (50 mL), the
layers were separated, and the aqueous layer was extracted
with DCM (2 × 50 mL). The combined organic layers were
washed with sat NH4Cl (50 mL), sat. NaHCO3 (50 mL), brine
(50 mL), dried over MgSO4, and evaporated to aﬀord the title
compound (1.29 g, Quant.) as a yellow foam, which was used
without further purification; νmax/cm
−1 (CHCl3) 3393, 3006,
2955, 2930, 2885, 1690, 1471, 1362, 1320, 1257, 1176, 1132,
1085 and 1062; 1H NMR (400 MHz, chloroform-d) δ 9.20 (1H,
s, NH), 7.31 (1H, q, J 1.2, C6H), 6.28 (1H, t, J 6.7, C1′H), 4.450
(1H, dd, J 11.2, 3.0, C5′HH) 4.45–4.38 (1H, m, C4′H), 4.36 (1H,
dd, J 11.2, 3.6, C5′HH), 4.05 (1H, app. q, J 3.6, C3′H), 3.06 (3H,
s, SO2CH3), 2.28 (1H, ddd, J 13.6, 6.4, 3.9, C2′HH), 2.17 (1H,
dt, J 13.6, 6.8, C2′HH), 1.93 (3H, d, J 1.3, CH3), 0.88 (9H, s, SiC-
(CH3)3), 0.09 (6H, s, Si(CH3)2);
13C NMR (101 MHz, chloro-
form-d) δ 163.9 (C4), 150.4 (C2), 135.6 (C6H), 111.7 (C5), 85.4
(C4′H, 84.3 (C1′H), 71.5 (C3′H), 68.5 (C6′H2), 40.6 (C2′H2), 37.8
(SO2CH3), 25.7 (SiC(CH3)3) 17.9, (SiC(CH3)3) 12.6 (CH3), −4.6¶For general experimental details please see the ESI.†
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(SiCH3), −4.8 (SiCH3); HRMS (ESI) C17H31N2O7SSi (M + H)
requires 435.1616; found 436.1624 and C17H30N2NaO7SSi
(M + Na) requires 457.1435; found 457.1444.
5′-Azide-3′-O-tert-butyldimethylsilyl deoxythymidine (10)
A solution of 5′-O-mesyl-3′-O-tert-butyldimethylsilyl deoxy-
thymidine (9) (1.29 g, 3.0 mmol) and sodium azide (580 mg,
9.0 mmol) in dry DMF (12 mL) under argon was heated to
100 °C for 14 h. The reaction was cooled to room temperature,
diluted with water (100 mL) and extracted with diethyl ether
(3 × 100 mL). The combined organic layers were washed with
brine (3 × 75 mL), over MgSO4, and evaporated. The residue
was purified by silica gel chromatography, eluting with petrol :
diethyl ether (1 : 1 to 0 : 1) to aﬀord the title compound
(686 mg, 61%) as a white foam; Rf 0.18 (petrol : diethyl ether
1 : 1); [α]22D +80 (c 0.78, CHCl3); νmax/cm
−1 (CHCl3) 3087, 3062,
3010, 2928, 2855, 2104, 1959, 1701, 1670, 1624, 1554, 1509,
1480, 1448, 1381, 1349, 1309, 1249, 1178, 1153; 1H NMR
(500 MHz, chloroform-d) δ 8.95 (1H, s, NH), 7.31 (1H, q, J 1.2,
C6H), 6.24 (1H, t, J 6.6, C1′H), 4.34 (1H, dt, J 7.0, 4.3, C3′H),
3.93 (1H, dt, J 4.4, 3.5, C4′H), 3.70 (1H, dd, J 13.3, 3.4, C5′HH),
3.49 (1H, dd, J 13.3, 3.6, C5′HH), 2.28 (1H, ddd, J 13.6, 6.6, 4.3,
C2′HH), 2.16 (1H, dt, J 13.7, 6.9, C2′HH), 1.94 (3H, d, J 1.3,
CH3), 0.88 (9H, s, SiC(CH3)3), 0.08 (6H, s, Si(CH3)2);
13C NMR
(126 MHz, chloroform-d) δ 163.8 (C4), 150.4 (C2), 135.5 (C6H),
111.5 (C5), 84.9 (C4′H, and C1′H), 71.8 (C3′H), 51.9 (C6′H2),
40.8 (C2′H2), 25.8 (SiC(CH3)3), 18.04 (SiC(CH3)3), 12.8 (CH3),
−4.54 (SiCH3), −4.77 (SiCH3); HRMS (ESI) C16H28N5O4Si
(M + H) requires 382.1905; found 382.1910 and
C16H27N5NaO4Si (M + Na) requires 404.1725; found 404.1737.
5′-Azide-3′-OH deoxythymidine (4)
To a stirred solution of 5′-azido-3′-O-tert-butyldimethylsilyl
deoxythymidine (10) (151 mg, 400 μmol) in THF (2.0 mL)
under an argon atmosphere, was added tetrabutylammonium
fluoride trihydrate (189 mg, 600 μmol). The resulting solution
was stirred at room temperature for 12 hours, and then the
volatile organics were evaporated. The residue was purified by
silica gel chromatography, eluting with EtOAc : MeOH (19 : 1)
to aﬀord the title compound (95 mg, 89%) as a white foam;
Rf 0.20 (EtOAc); [α]
22
D +114 (c 1.0, CHCl3); νmax/cm
−1 (CHCl3);
3390, 3009, 2956, 2105, 1690, 1471, 1438, 1262; 1H NMR
(500 MHz, Methanol-d4) δ 7.54 (1H, q, J 1.2, C6H), 6.26 (1H, t,
J 6.8, C1′H)), 4.34 (1H, dt, J 6.5, 4.1, C3′H), 3.96 1H, (dt, J 5.0,
3.8, C5′H), 3.63 (1H, dd, J 13.2, 3.7, C5′HH), 3.57 (1H, dd,
J 13.2, 5.1, C5′HH), 2.31 (1H, dd, J 13.7, 6.6, C2′HH), 2.25 (1H,
ddd, J 13.7, 6.6, 3.9, C2′HH), 1.89 (3H, d, J 1.3, CH3).
13C NMR
(126 MHz, Methanol-d4) δ 166.3 (C4), 152.3 (C2), 137.7 (C6H),
111.9 (C5), 86.4 (C4′H or C1′H) 86.3 (C4′H or C1′H), 72.5 (C3′
H), 53.4 (C6′H2), 40.2 (C2′H2), 12.5 (CH3); HRMS (ESI)
C10H14N5O4 (M + H) requires 268.1040; found 268.1044 and
C10H14N5NaO4 (M + Na) requires 290.0859; found 290.0858.
TLMorpholino-3′-O-tert-butyl silyl dimer T-T (11)
To a microwave vial containing the morpholino thymidine (3)
(290 mg, 500 μmol) and the azide thymidine (10) (190 mg,
500 μmol) in THF : tBuOH : H2O (3 : 2 : 1 ratio, total volume
2 mL) was added copper iodide (47.0 mg, 250 μmol). The vial
was sealed, stirred and irradiated in a Biotage microwave at
80 °C (approximately power of irritation 16 W) for 312 h. After
cooling to room temperature the vial was removed, and the sol-
vents were removed in vacuo to aﬀord a residue, which was pur-
ified by silica gel chromatography, eluting with DCM :MeOH
(40 : 1 to 30 : 1) to aﬀord the title compound (339 mg, 72%) as
a colourless foam; Rf 0.21 (DCM :MeOH 25 : 1); [α]
24
D +66
(c 0.74, CHCl3); νmax/cm
−1 (CHCl3) 3603, 3390, 3305, 3200,
2934, 2838, 2552, 1905, 1713, 1681, 1633, 1611, 1584, 1490,
1456; 1H NMR (400 MHz, chloroform-d) δ 9.49 (1H, s, NH),
9.38 (1H, s, NH), 7.61 (1H, s, CvCHN), 7.46–7.37 (2H, m, Ph),
7.35–7.15 (8H, m, 4 × Ar, C6H, 3 × Ph), 6.86–6.76 (4H, m, Ar),
6.68 (1H, d, J 1.4, C6H), 6.07 (1H, t, J 6.6, C1′H), 5.79 (1H, dd,
J 9.7, 2.6, C1′H),4.72–4.56 (2H, m, NCH2C), 4.45 (1H, dt, J 7.0,
5.2, C3′H), 4.15–4.00 (2H, m, C4′H and C4′H), 3.80 (1H, d,
J 13.9, OC5′HH) 3.78 (6H. s, OCH3), 3.68 (1H, d, J 13.9, OC5′
HH), 3.26 (1H, dd, J 9.7, 5.3, NC5′HH), 3.09–2.97 (2H, m, NC5′
HH and NCHH), 2.91 (1H, d, J 10.9, NCHH), 2.36–2.18 (2H, m,
C2′H2), 2.10 (1H, t, 10.7, NCHH), 2.04 (1H, t, 10.7, NCHH),
1.92 (3H, d, J 1.2, CH3), 1.92 (3H, d, J 1.2, CH3), 0.89 (9H, s, SiC
(CH3)3), 0.11 (3H, s, SiCH3), 0.08 (3H, s, SiCH3);
13C NMR
(101 MHz, chloroform-d) δ 163.8 (2 × C4), 158.6 (2 × ArC), 150.3
(C2), 150.2 (C2), 144.8 (ArC), 143.86 (Cv) 136.4 (C6H), 135.9
(ArC), 135.8 (ArC), 135.62 (C6H), 130.2 (2 × ArCH), 130.14 (2 ×
ArCH), 128.23 (2 × PhCH), 127.9 (2 × PhCH), 126.9 (PhCH), 124.7
(vCHN), 113.2 (4 × ArCH), 111.6 (C5), 110.9 (C5), 86.6 (Ar3CO),
86.2 (C1′H), 84.2 (C4′H), 79.8 (C1′H), 75.8 (C4′H), 72.0 (C3′H),
64.6 (NC5′H2), 55.9 (NCH2), 55.3 (2 × OCH3), 54.4 (NCH2), 52.8
(OC5′H2), 50.9 (NCH2C), 39.4 (C2′H2), 25.8 (SiC(CH3)3), 17.9
(SiC(CH3)3), 12.70 (2 × CH3), −4.5 (SiCH3), −4.6 (SiCH3); HRMS
(ESI +ve) C50H63N8O10Si (M + H
+) requires 963.4431, found
963.4436, and C50H62N8NaO10Si (M + Na
+) requires 985.4250,
found 985.4231.
TLMorpholino-3′-OH dimer T-T (12)
Method 1 – direct CuI catalysed cycloaddation with an
unprotected azide. To a microwave vial containing the mor-
pholino thymidine (3) (203 mg, 350 μmol) and the azide thy-
midine (4) (95 mg, 350 μmol) in THF : tBuOH : H2O (3 : 2 : 1
ratio, total volume 1.75 mL) was added copper iodide
(33.0 mg, 175 μmol). The vial was sealed, stirred and irradiated
in a Biotage microwave at 80 °C (approximately power of irri-
tation 16 W) for 312 h. After cooling to room temperature the
vial was removed, and the solvents were removed in vacuo to
aﬀord a residue, which was purified by silica gel chromato-
graphy, eluting with DCM :MeOH (12 : 1 to 10 : 1) to aﬀord the
title compound (223 mg, 75%) as a white foam; Rf 0.12 (DCM :
MeOH 10 : 1); [α]24D −7.13 (c 1.0, CHCl3); νmax/cm−1 (ATR) 3390,
3008, 2961, 1690, 1608, 1509, 1490, 1456; 1H NMR (500 MHz,
chloroform-d) δ 9.93 (1H, s, NH), 9.86 (1H, s, NH), 7.72 (1H, s,
CvCHN), 7.48–7.41 (2H, m, Ph), 7.37–7.25 (7H, m, 4 × Ar,
C6H, 2 × Ph), 7.26–7.18 (1H, m, Ph), 6.95 (1H, s, C6H),
6.89–6.80 (4H, m, Ar), 6.07 (1H, t, J 6.6, C1′H), 5.75 (1H, dd,
J 8.8, C1′H), 4.74–4.68 (2H, m, NCH2C), 4.51 (1H, bs, C3′H),
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4.39 (1H, bs, OH), 4.24 (1H, m, C4′H), 4.14–4.05 (1H, m, C4′H),
3.89 (1H, d, J 13.6, OC5′HH), 3.80 (6H, s, 2 × OCH3), 3.63 (1H,
d, J 13.6, OC5′HH), 3.30 (1H, dd, J 9.7, 5.1, NC5′HH), 3.10 (1H,
dd, J 9.7, 5.0, NC5′HH), 3.07–2.97 (2H, m, NCHH and NCHH),
2.33–2.26 (2H, m, C2′H2), 2.18 (1H, t, J 11.0, NCHH), 1.97 (1H,
t, J 10.4, NCHH), 1.92 (3H, s CH3), 1.89 (3H, s, CH3);
13C NMR
(126 MHz, chloroform-d) δ 164.0 (C4), 163.9 (C4), 158.5 (2 ×
ArC), 150.5 (C2), 150.4 (C2), 144.6 (Cv), 143.8 (ArC), 136.6
(C6H), 135.8 (ArC), 135.7 (ArC), 135.5 (C6H), 130.1 (2 × ArCH),
130.0 (2 × ArCH), 128.1 (2 × ArCH), 127.8 (2 × ArCH), 126.9
(PhCH), 124.6 (vCHN), 113.1 (4 × ArCH), 111.3 (C5), 111.0 (C5),
86.52 (C1′H), 86.1 (Ar3CO), 83.9 (C4′H), 79.9 (C1′H), 75.7 (C4′
H), 71.6 (C3′H), 64.3 (NC5′H2), 55.4 (NCH2), 55.2 (2 × OCH3),
54.9 (NCH2), 52.7 (OC5′H2), 51.4 (NCH2C), 38.9 (C2′H2), 12.6
(CH3), 12.5 (CH3); HRMS (ESI +ve) C44H49N8O10 (M + H
+)
requires 849.3566, found 849.3644.
Method 2; TBAF deprotection of TBS protected triazole. To
a stirred solution of the TLmorpholino-3′-O-tert-butyl silyl
dimer T-T (11) (339 mg, 358 μmol) in THF (2.0 mL) under an
argon atmosphere, was added tetrabutylammonium fluoride
trihydrate (141 mg, 447 μmol). The resulting solution was
stirred at room temperature for 12 hours, then ammonium
chloride (28 mg, 540 μmol) was added and stirred
for 5 minutes. The resulting reaction mixture was dry
loaded on to silica and purified by silica gel chromatography,
eluting with DCM :MeOH (12 : 1 to 10 : 1) to aﬀord the
title compound (251 mg, 82%) as a white foam; Rf 0.12
(DCM :MeOH 10 : 1).
TLMorpholino phosphoramidite T-T (13)
To a stirred solution of the TLMorpholino-3-OH dimer T-T (12)
in DCM under an argon atmosphere at room temperature was
added N,N-diisopropylethylamine (98 μL, 561 μmol) followed
by 2-cyanoethyl N,N-diisopropylchlorophosphoramidite
(59.0 mg, 266 μmol) dropwise over 1 minute, then stirred at
room temperature for 24 h. The solvent was blown oﬀ with a
stream of nitrogen gas, and the residue was purified by silica
column chromatography, eluting with DCM :MeOH (20 : 1 to
15 : 1) to aﬀord an analytical pure sample of the title com-
pound (38 mg, 14%) as a white foam along with the bulk
material (167 mg ca. 60%) containing small amounts of
2-cyanoethyl N,N-dipropylphosphonamidate as an oﬀ white
foam; Rf 0.15 (DCM :MeOH 15 : 1); νmax/cm
−1 (CHCl3) 3698,
3665, 3391, 3212, 2857, 2552, 2300, 2105, 2047, 1908, 1731,
1681, 1633, 1592, 1490 and 1455; 1H NMR (500 MHz, chloro-
form-d) δ 8.66 (1H, s, NH), 8.66 (1H, s, NH), 7.63 and 7.59 (1H,
2 × s, CvCHN), 7.48–7.41 (2H, m, Ph), 7.35–7.23 (7H, m, 4 ×
Ar, C6H, 2 × Ph), 7.23–7.17 (1H, m, Ph), 6.87–6.77 (5H, m, Ar
and C6H), 6.12 (1H, m, C1′H), 5.77 (1H, m, C1′H), 4.82–4.54
(3H, m, NCH2C and C3′H), 4.34–4.22 (1H, m, C4′H), 4.07–4.02
(1H, m, C4′H), 3.90–3.85 (1H, m, OCHH), 3.84–3.79 (1H, m,
OC5′HH), 3.79 (6H, s, 2 × OCH3), 3.84–3.68 (1H, m, OCHH),
3.69–3.54 (3H, m, OC5′HH and 2 × NCH), 3.26 (1H, dd, J 9.7,
5.1, NC5′HH), 3.08–2.96 ((2H, m, NC5′HH and NCHH), 2.92
(1H, m, NCHH), 2.75–2.68 (1H, m, CHHCN), 2.71–2.59 (1H, m,
CHHCN), 2.51–2.22 (2H, m, C2′H2), 2.09 (1H, t, J 11.0, NCHH),
2.07–1.97 (1H, m, NCHH), 1.92 (3H, s CH3), 1.90 (3H, s, CH3),
1.20 (12H, m, NCH(CH3)2);
13C NMR (500 MHz, chloroform-d)
due to the presence of a diastereomeric mixture at the phos-
phorus(III) centre and coupling from phosphorus the 13C NMR
could not be unambiguously assigned but the spectra are
included in this ESI;† 31P NMR (162 MHz, CDCl3) δ 149.2;
HRMS (ESI +ve) C53H66N10O11P (M + H
+) requires 1049.4645,




To a stirred solution of 5′-O-DMT thymidine (1.40 g,
2.55 mmol) in THF (25 mL) at 0 °C was added sodium hydride
(257 mg, 6.4 mmol) in small portions over 5 min. The result-
ing solution was stirred at 0 °C for 30 min, then at room temp
for 1 h. The solution was cooled to 0 °C and propargyl
bromide (285 μL, 3.18 mmol) was added. The solution was
stirred at 0 °C for 30 min, then at room temp for 5 h. The reac-
tion was quenched by the addition of water (1 mL), and the
volatile organic were removed by evaporation. The residue was
partitioned between water (25 mL) and DCM (25 mL), the
aquous layer was extracted with DCM (3 × 25 mL). The com-
bined organic layers were washed with brine (2 × 25 mL), dried
over MgSO4, and evaporated in vacuo to aﬀord a residue, which
was purified by silica gel chromatography, eluting with DCM :
MeOH (38 : 1 to 19 : 1) to aﬀord the title compound (1.15 g,
77%) as a white foam; Rf 0.4 (DCM :MeOH 19 : 1); [α]
24
D 33.0
(c 1.0, CHCl3); νmax/cm
−1 (ATR); 3385, 3190, 2950, 1930, 1695,
1631, 1611, 1491; 1H NMR (400 MHz, chloroform-d) δ 8.75
(1H, br s, NH), 7.63 (1H, s, C6H), 7.46–7.41 (2H, m, Ar),
7.36–7.25 (7H, m, Ar), 6.89–6.85 (4H, m, Ar), 6.36 (1H, d, J 8.0
and 5.7, C1′H), 4.53 (1H, dt, J 5.3 and 2.2, C4′H), 4.21 (1H, dd,
J 15.9 and 2.3, OCH̲HCCH), 4.21–4.16 (1H, m, C5′H), 4.16 (1H,
dd, J 15.9 and 2.3, OCH̲HCCH), 3.82 (6H, s, 2 × OCH3),
3.50 (1H, dd, J 10.6 and 3.0, C6′HH), 3.38 (1H, dd, J 10.6
and 2.7, C6′HH), 2.54 (1H, ddd, J 13.9, 5.7 and 2.2, C2′HH),
2.44 (1H, t, J 2.3, CCH), 2.26 (1H, ddd, J 13.9, 8.0 and 6.3, C2′
HH), 1.53 (3H, s, CH3);
13C NMR (101 MHz, chloroform-d )
δ 163.8 (C4), 158.8 (2 × C), 150.4 (C2), 144.5 (C), 135.6 (C6H),
135.5 (2 × C), 130.2 (4 × CH), 128.2 (2 × CH), 128.1 (2 × CH),
127.3 (CH), 113.4 (4 × ArCH), 111.3 (C5H), 87.1 (C), 84.91 (C1′
H), 84.0 (C5′H), 79.2 (C), 78.6 (C4′H), 75.2 (CH), 63.6 (C5′H2),
56.7(CH2), 55.4 (2 × OCH3), 37.9 (C2′H2), 12.0 (CH3); HRMS
(ESI +ve) C34H34N2NaO7 (M + Na
+) requires 605.2258, found
605.2247.
Triazole-T-T dimer (16)
To a microwave vial containing the 3′-O-propargyl thymidine
(15) (1.164 g, 2.0 mmol) and the azide thymidine (4) (534 mg,
2.0 mmol) in THF : tBuOH : H2O (3 : 2 : 1 ratio, total volume
12 mL) was added copper iodide (188 mg, 1.0 mol). The vial
was sealed, stirred and irradiated in a Biotage microwave at
80 °C (approximately power of irritation 16 W) for 312 h. After
cooling to room temperature the vial was removed, and the
solvents were removed in vacuo to aﬀord a residue, which was
purified by silica gel chromatography, eluting with DCM :
Organic & Biomolecular Chemistry Paper






















































































MeOH (20 : 1 to 10 : 1) to aﬀord the title compound (1.47 g,
87%) as a white foam; Rf 0.35 (DCM :MeOH 10 : 1); [α]
24
D 5.2
(c 1.0, CHCl3); νmax/cm
−1 (ATR) 3392, 3010, 2963, 1691, 1604,
1493, 1460; 1H NMR (400 MHz, DMSO-d6) δ 11.35 (1H, br s,
NH), 11.31 (1H, br s, NH), 8.08 (1H, s, triazole-CH), 7.51 (1H, s,
C6H), 7.40–7.29 (4H, m, Ar), 7.33 (1H, s, C6H), 7.28–7.22 (5H,
m, Ar), 6.90 (4H, d, J 8.7 Hz, Ar), 6.16 (1H, app t, J 6.4 Hz C1H),
6.14 (1H, app t, J 6.4 Hz C1H), 5.50 (1H, d, J 4.4, OH), 4.70 (1H,
dd, J 14.3 and 4.4, NC5′HH), 4.59 (1H, dd, J 14.3 and 7.7, NC5′
HH), 4.60–4.52 (2H, m, OCH2C), 4.45–4.37 (1H, m, C3′H),
4.31–4.24 (1H, m, C3′H), 4.10–4.02 (2H, m, C4′H and C4′H),
3.74 (6H, s, 2 × OCH3), 3.26 (1H, dd, J 10.5, 3.8 Hz, OC5′HH),
3.17 (1H, dd, J 10.5, 3.2 Hz, OC5′HH), 2.43–2.25 (2H, m,
C2′HH), 2.25–2.04 (2H, m, C2′HH), 1.78 (3H, s, CH3), 1.43 (3H,
s, CH3);
13C NMR (101 MHz, DMSO) δ 163.6 (2 × C4), 158.17
(2 × C), 150.37 (2 × C2), 144.6 (C), 143.7 (C), 136.0 (C6),
135.5 (C6), 135.4 (C), 135.1 (C), 129.7 (4 × CH), 127.9 (2 × CH),
127.6 (2 × CH), 126.8 (CH), 124.7 (triazole-CH), 113.3
(4 × ArCH), 109.8 (C5H), 109.7 (C5H), 86.04 (C), 84.02
(CH), 83.93 (CH), 83.78 (CH), 82.87 (CH), 78.75 (CH), 70.72
(CH), 63.77 (CH2), 61.77 (CH2), 55.05 (2 × OCH3), 51.17 (CH2),
37.9 (C2′H2), 36.5 (C2′H2), 12.1 (CH3), 11.9 (CH3); HRMS (ESI
+ve) C44H47N7NaO11 (M + Na
+) requires 872.3226, found
872.3215.
Triazole-T-T dimer phosphoramidite (17)
To a stirred solution of the triazole-T-T dimer (16) (493 mg,
0.58 mmol) in DCM (1.2 mL) under an argon atmosphere at
room temperature was added N,N-diisopropylethylamine
(182 μL, 1.05 mmol) followed by 2-cyanoethyl N,N-diisopropyl-
chlorophosphoramidite (125 mg, 0.58 mmol) dropwise over
1 minute, then stirred at room temperature for 24 h. The
solvent was blown oﬀ with a stream of nitrogen gas, and the
residue was purified by silica column chromatography, eluting
with DCM :MeOH (20 : 1 to 15 : 1) to aﬀord the title compound
(391 mg, ca. 64%) containing 2-cyanoethyl N,N-diisopropyl-
phosphonamidate as an oﬀ white foam; Rf 0.21 (DCM :MeOH
15 : 1); νmax/cm
−1 (ATR) 3700, 3669, 3384, 3219, 2860, 2550,
2310, 2109, 1911, 1733, 1686, 1495 and 1459; 1H NMR
(500 MHz, chloroform-d) δ 9.20 (2H, br s, NH), 7.69 and 7.65
(1H, 2 × s, triazole-CH), 7.60 (1H, s, C6H), 7.42–7.37 (2H, m,
Ar), 7.37–7.21 (7H, m, Ar), 6.90–6.83 (4H, m, Ar), 6.78–6.73
(1H, 2 × s, C6H), 6.38–6.32 (1H, m, C1H), 6.21–6.13 (1H, m,
C1H), 4.78–4.57 (5H, m, 2 × CH2 and OCH), 4.40–4.11 (3H, m,
3 × CH), 3.99–3.70 (2H, m, CH2), 3.81 (6H, s, 2 × OCH3),
3.68–3.45 (3H, m, 2 × CH and CHH), 3.38–3.32 (1H, m, CHH),
2.80–2.75 (1H, m, CHHCN) 2.70–2.65 (1H, m, CHHCN),
2.57–2.20 (4H, m, C2′HH and C2′HH), 1.90–1.87 (3H, m, CH3),
1.47 (3H, s, CH3); 1.26–1.18 (12H, m, NCH(CH3)2); δ
13C NMR
(500 MHz, chloroform-d) due to the presence of a diastereo-
meric mixture at the phosphorus(III) centre and coupling
from phosphorus the 13C NMR could not be unambiguously
assigned but the spectra are included in this ESI;†
31P NMR (162 MHz, CDCl3) δ 149.1; HRMS (ESI +ve)
C53H65N9O12P (M + H
+) requires 1050.4485, found 1050.4464.
Conclusions
We have shown that the CuAAC reaction can be used to syn-
thesise a new DNA mimic containing a triazole-linked morpho-
lino (TLMO) internucleotide modification. Phosphoramidite
reagents 13 and 17 were synthesised and their compatibility
with automated solid phase synthesis was demonstrated. UV
melting studies showed that incorporation of the TLMO modifi-
cation provided an improved Tm value for binding to RNA
when compared to the previously reported triazole-containing
oligomers. Structural characterisation, and biological evalu-
ation of the TLMO-modified oligomers is underway and the
results of this work will be reported in due course.
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